IONS: Analysts, Options Traders, and the Crowd All Converge Before Earnings

Ionis Pharmaceuticals has drawn simultaneous bullish signals from three separate directions in the week before its October 28 earnings print. BMO Capital upgraded the stock this morning. Options positioning sits nearly two standard deviations below its 20-day mean on put-call ratio. Retail attention has spiked to levels rarely seen in the past 90 days.

The Upgrade That Reopened the Bull Case

BMO Capital's David Lebowitz moved IONS from Market Perform to Outperform this morning, raising his price target to $66 from $54. That implies 49% upside from the October 21 close of $44.27.

He is not alone in turning more constructive. UBS upgraded to Buy on October 15, lifting its target to $88 from $46. The consensus price target now sits at $82.91, with 12 buy ratings against 4 holds.

The backdrop for these moves is a stock that had been beaten down heavily. An earlier ORTEX note flagged shares off 43.8% year-to-date through late September. The two upgrades in one week suggest a growing view among analysts that the selloff overshot.

The bull case, as framed in the ORTEX analyst summary, rests on a pipeline producing multiple near-term catalysts: sefaxersen's Phase 3 win in IgAN, Tryngolza's 85% reduction in acute pancreatitis events, and a series of commercial launches from 2023 through 2025. The bear case centres on slower-than-expected commercial uptake, payer pressure, and a break-even target still two years out.

Options Positioning Shifts Toward Calls

The put-call ratio for IONS stood at 0.60 on October 21, against a 20-day mean of 0.66. The z-score of minus 2.02 places current positioning almost two standard deviations below that mean, the most call-heavy skew in recent weeks. The 52-week range runs from 0.45 to 1.21, so the reading is not at an extreme on that broader scale, but the directional shift ahead of the October 28 earnings date is notable.

Short interest sits at 13.6% of free float, up roughly 3.8% over the past month, and the ORTEX short score is 56.4. Despite that elevated short position, the borrow market is loose: availability stands at 2,110%, meaning there are more than 21 shares available to borrow for every one already borrowed. Cost to borrow is 0.47%, a low level.

Retail Attention at a Multi-Month High

ORTEX Alt Data recorded a retail attention z-score of 5.39 on October 19, measured against IONS's own 90-day history of English Wikipedia article views and ORTEX stock page visits. That is the most elevated reading in the dataset's recent window.

The same Alt Data layer shows Medicaid dollars reimbursed for an Ionis drug up 1,658% on Q1 last year, and Medicaid prescriptions up 1,650%, based on the latest available CMS data covering the period ending January 2026. These figures reflect real-world dispensing growth from a low base, and earnings are six days away.

Data Summary

• BMO Capital upgrades to Outperform, PT raised to $66 from $54; consensus target $82.91 across 12 buys, 4 holds
• Put-call ratio 0.60, z-score minus 2.02 versus 20-day mean
• Retail attention z-score 5.39, per Wikipedia views and ORTEX stock page data as of October 19
• Short interest 13.6% of free float, up 3.8% over one month; availability 2,110%
• Cost to borrow 0.47%; ORTEX short score 56.4
• Next earnings: October 28